All News
Filter News
Found 809,127 articles
-
US Cancer Antibodies Market Size USD 85 Billion Opportunity By 2028
2/18/2022
US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights.
-
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China
2/18/2022
TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug ("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor, for the treatment of B-cell lymphomas on January 24, 2022, and TransThera will initiate the Phase I clinical trials in the U.S. soon.
-
OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
2/18/2022
OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain.
-
New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks
2/18/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1.
-
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances
2/18/2022
Codiak BioSciences, Inc. (NASDAQ: CDAK), today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science’s journal, Science Advances.
-
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)
2/18/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from the Phase 2 GALAXI 1 clinical trial showing the majority (57.4-73 percent) of adults with moderately to severely active Crohn's disease (CD) who were treated with TREMFYA® (guselkumab) achieved clinical remission (Crohn's Disease Activity Index [CDAI]<150)a at week 48.
-
Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study
2/18/2022
Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical remission at 12 weeks compared to patients taking placebo in Eli Lilly and Company's (NYSE: LLY) pivotal LUCENT-1 Phase 3 study.
-
Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition
2/18/2022
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug Administration (FDA) and are the only ablation catheters approved to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
-
European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
2/18/2022
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib).
-
Clinical Genomics Announces New Publication from Flinders Medical Centre, Highlighting the Use of COLVERA® as a Quantitative ctDNA Biomarker for Response to Colorectal Cancer Therapy
2/18/2022
Clinical Genomics today announced a new publication from researchers at the prestigious Flinders Centre for Innovation in Cancer.
-
Sirona Medical Acquires Nines and Key Personnel
2/18/2022
Sirona Medical today announced the acquisition of Nines' AI capabilities, including its clinical data pipeline, machine learning engines, AI powered radiology workflow management and analytics tools, as well as two FDA-cleared medical devices.
-
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
2/18/2022
Atara Biotherapeutics, Inc. today reported Memorial Sloan Kettering Cancer Center’s (MSK) notification to the U.S. Food and Drug Administration (FDA) of a fatal serious adverse event (SAE) associated with a patient treated in the ongoing Phase 1 MSK-conducted dose-escalation clinical study of autologous mesothelin CAR T, ATA2271.
-
Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
2/18/2022
Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO ® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma.
-
Advancium Health Network and Silicon Valley Bank to Launch Not-For-Profit Cure Innovation Labs℠ Accelerating Early Stage Life Science Companies
2/18/2022
Advancium Health Network and Silicon Valley Bank to Launch Not-For-Profit Cure Innovation Labs ℠ Accelerating Early Stage Life Science Companies.
-
Novo Integrated Sciences’ IoNovo for Kids Pure Iodine Oral Spray Granted Natural Product Number (NPN) by Health Canada
2/18/2022
Novo Integrated Sciences, Inc. today announced that its wholly owned subsidiary, Novo Healthnet Limited, has been granted a Natural Product Number (NPN) by Health Canada for its IoNovo for Kids pure iodine oral spray branded product line.
-
EarliTec Diagnostics Announces $19.5 Million Financing to Advance Autism Diagnosis and Treatment in Children as Young as 16 Months of Age
2/18/2022
EarliTec Dx, Inc. announced today a $19.5 million financing to further its mission of making earlier ASD identification and treatment accessible to children everywhere.
-
Moderna Expands Its mRNA Pipeline with Three New Development Programs
2/18/2022
Moderna, Inc. today announced that it is expanding its mRNA pipeline with three new development programs.
-
Zynex Anticipates No Material Change in Revenue from Switch in United Health Care Prescription Coverage
2/18/2022
Zynex, Inc today responded to a short report related to United Health Care's prescription coverage of its products.
-
Dante Labs Partnering with The Renato Dulbecco Foundation to advance personalized medicines for cancer, COVID-19 and rare diseases
2/18/2022
Dante Labs today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology and COVID-19.
-
Applied UV Applauds New Policy Guidance Issued by the Centers for Medicare & Medicaid Services (CMS)
2/18/2022
Applied UV, Inc. applauds the Centers for Medicare and Medicaid Services (CMS) guidance pertaining to Tools to Improve Facility Air Quality held on February 4, 2022 during a nursing home call with stakeholders.